Array Biopharma (ARRY) Misses Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $6.37 -1.39%
EPS Growth %: -52.0%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: -52.0%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $36.99 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- Simply Good Foods (SMPL) Tops Q3 EPS by 7c; offers outlook
- Delta Air shares slip despite strong outlook, Melius says
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
